Clinical Trials Center of Middle Tennessee
Franklin, Tennessee 37067-5665
1 studies enrolling now · 13 studies all time
What they study most
COVID-19, COVID-19 Infection, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Hypersensitivity Pneumonitis, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Interstitial Lung Disease With Systemic Sclerosis, Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Long COVID
Studies at this site
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis — Recruiting now
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
- A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — Running, not enrolling
- A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis — Running, not enrolling
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Running, not enrolling
- A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis — Stopped early
- RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms — Completed
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Running, not enrolling
- Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis — Completed
- PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19 — Stopped early
- CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 — Completed
- Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
- Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine — Completed